Abstract
Background Severity is an important factor for inclusion of diseases on expanded carrier screening (ECS) panels. Here, we applied a validated algorithm that objectively classifies diseases into severity categories to 176 genes on a clinically available ECS panel. We then mapped disease traits from the algorithm to severity-related criteria cited by the American College of Obstetricians and Gynecologists (ACOG).
Methods Eight genetic counselors (GCs), followed by four medical geneticists (MDs), applied the algorithm to subsets of the 176 genes. MDs and GCs then determined which disease traits met ACOG severity criteria.
Results Upon initial GC and MD review, 107/176 genes (61%) and 133/176 genes (76%), respectively, had concordant classifications, with consensus reached for all genes. Final severity classifications were 68 (39%) profound, 71 (40%) severe, 36 (20%) moderate, and one (1%) mild. The vast majority of genes (170 out of 176) met at least one of ACOG’s four severity criteria.
Conclusion This study classified the severity of a large set of Mendelian genes by collaborative clinical expert application of an algorithm. Further, it clarified and operationalized difficult to interpret ACOG severity criteria via mapping of disease traits, thereby promoting consistency of ACOG criteria interpretation across laboratories.
What’s already known about this topic?
Disease severity is an important consideration for disease inclusion on expanded carrier screening panels.
An algorithm that objectively classifies diseases into severity categories has been published and validated.
What does this study add?
176 genes were classified into severity categories.
The algorithm was used to bring clarity to American College of Obstetricians and Gynecologist’s (ACOG’s) severity criteria that are not easily interpretable.
170 of 176 genes met at least one of ACOG’s severity criteria.
Data Availability Statement The data that support the findings of this study have been completely reported in this manuscript and shared in the Figures and Supplementary Material.
Competing Interest Statement
Aishwarya Arjunan, Holly Bellerose, Katherine Johansen Taber, Raul Torres, Jennifer Tarpinian, and Gabriel A. Lazarin are all current or former employees of Myriad Women’s Health. Jodi D. Hoffman, Brad Angle, Robert Nathan Slotnick, Brittany N. Simpson, Andrea M. Lewis, Pilar L. Magoulas, Kelly Bontempo, Jeanine Schulze, Jennifer Tarpinian, Jessica A. Bucher, Richard Dineen, and Allison Goetsch all received honoraria from Myriad Women’s Health to participate in this study. There are no other conflicts of interest to declare.
Funding Statement
No external funding was received.
Author Declarations
All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The datasets generated during and/or analyzed during the current study are available from the corresponding author on request.
